Develops bioprocessing systems for manufacturing biological drugs.
Jun 2026Revenue $785M/yrExpenses $720M/yr
No trend
Figures by year
Is Repligen profitable?
Yes. In the 12 months to Jun 2026, revenue was $785M and expenses $720M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $738M | $683M | $55.2M |
| Dec 2024 | $634M | $670M | −$35.1M |
| Dec 2023 | $632M | $585M | $47.7M |
| Dec 2022 | $802M | $577M | $225M |
| Dec 2021 | $671M | $503M | $167M |
| Dec 2020 | $366M | $296M | $69.8M |
| Dec 2019 | $270M | $234M | $36.1M |
| Dec 2018 | $194M | $168M | $26.0M |
| Dec 2017 | $141M | $127M | $14.0M |
| Dec 2016 | $105M | $88.6M | $16.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.